Capital gets you started. Capability keeps you going.

TL;DR

Capital gets you started. Capability keeps you going. The Gulf has sovereign capital, speed of decision making, and genuine political will — three things most emerging ecosystems lack. What it still needs is the operational layer that turns investment into outcomes, and an investor base that understands the life sciences risk profile (not fintech). China’s playbook is useful: build the stack — regulatory reform, CDMO capacity at scale, talent. The Gulf can go one step further by building fast, founder-friendly pathways to first-in-human that are globally credible from day one. The question isn’t whether the ambition exists. It’s whether coordination will match it.

Capital gets you started. Capability keeps you going.

But the connective tissue between them decides whether a life sciences ecosystem actually works.

Yesterday at WHX Dubai, I joined Aman Kumar, MD (Oaktree Life Sciences Lending), Mohamed ElShaarawy (GM Roche Middle East), and our excellent moderator Mazin Gadir PhD MSc BEng PMP Prosci LSSGB EBAS Agile (Alvarez & Marsal) to discuss what it really takes to build biotech and life sciences in this region.

My take: the Gulf has three things most emerging ecosystems lack: sovereign capital, speed of decision making, and genuine political will.

What it still needs is the operational layer that turns investment into outcomes, and an investor base that understands the life sciences risk profile. techbio and biotech is not fintech. Timelines are 5–10 years, outcomes can be binary, and value creation is milestone driven.

China’s playbook is extremly useful here. They didn’t just fund startups. They built the stack: regulatory reform, industrial infrastructure (CDMO capacity at scale), and talent.

The Gulf can go one step further: build fast, founder-friendly pathways to first-in-human that are globally credible from day one. Smart regulators that listen, CROs that can execute trials to international standards, CDMOs that can manufacture to GMP, and clinical access through real health systems.

If you get that right, the founder question becomes easy to answer: why build in Abu Dhabi instead of Kendall Square or Oxford? Because it’s the fastest path to patients that still “counts” globally.

The question isn’t whether the ambition exists. It’s whether coordination will match it.

Key takeaways

• The Gulf has three things most emerging life sciences ecosystems lack: sovereign capital, speed of decision making, and genuine political will.
• The missing layer is the operational tissue that turns capital into outcomes, plus an investor base that understands life sciences risk (not fintech).
• Life sciences timelines are 5–10 years, outcomes can be binary, and value creation is milestone-driven. Capital that expects fintech-style return curves will misread every signal.
• China’s playbook: build the stack — regulatory reform, industrial infrastructure (CDMO capacity at scale), and talent. Don’t just fund startups.
• The Gulf can go further by building fast, founder-friendly pathways to first-in-human that are globally credible from day one: smart regulators, CROs to international standards, GMP-capable CDMOs, real health system access.
• If that’s in place, the founder question answers itself on commercial grounds: Abu Dhabi becomes the fastest path to patients that still counts globally.
• The ambition exists. The open variable is coordination.